NYSE - Delayed Quote USD

Thermo Fisher Scientific Inc. (TMO)

Compare
555.47 -2.45 (-0.44%)
At close: November 4 at 4:00 PM EST
551.00 -4.47 (-0.80%)
Pre-Market: 4:17 AM EST
Loading Chart for TMO
DELL
  • Previous Close 557.92
  • Open 556.68
  • Bid 541.44 x 900
  • Ask --
  • Day's Range 550.15 - 559.56
  • 52 Week Range 437.26 - 627.88
  • Volume 815,100
  • Avg. Volume 1,223,403
  • Market Cap (intraday) 212.467B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 34.85
  • EPS (TTM) 15.94
  • Earnings Date Jan 31, 2025 - Feb 5, 2025
  • Forward Dividend & Yield 1.56 (0.28%)
  • Ex-Dividend Date Sep 13, 2024
  • 1y Target Est 657.43

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMO

View More

Performance Overview: TMO

Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMO
4.86%
S&P 500
19.77%

1-Year Return

TMO
22.48%
S&P 500
31.07%

3-Year Return

TMO
12.90%
S&P 500
22.57%

5-Year Return

TMO
85.14%
S&P 500
86.27%

Compare To: TMO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMO

View More

Valuation Measures

Annual
As of 11/4/2024
  • Market Cap

    212.47B

  • Enterprise Value

    241.14B

  • Trailing P/E

    34.83

  • Forward P/E

    23.42

  • PEG Ratio (5yr expected)

    2.09

  • Price/Sales (ttm)

    5.04

  • Price/Book (mrq)

    4.34

  • Enterprise Value/Revenue

    5.69

  • Enterprise Value/EBITDA

    20.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.48%

  • Return on Assets (ttm)

    4.71%

  • Return on Equity (ttm)

    12.94%

  • Revenue (ttm)

    42.37B

  • Net Income Avi to Common (ttm)

    6.14B

  • Diluted EPS (ttm)

    15.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.65B

  • Total Debt/Equity (mrq)

    72.33%

  • Levered Free Cash Flow (ttm)

    6.82B

Research Analysis: TMO

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 10.6B
Earnings 1.63B
Q4'23
Q1'24
Q2'24
Q3'24
0
2B
4B
6B
8B
10B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

600.00
657.43 Average
555.47 Current
767.00 High
 

Company Insights: TMO

Research Reports: TMO

View More
  • Thermo Fisher Sees Demand Slowly Return

    Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).

    Rating
    Price Target
     
  • Thermo Fisher Earnings: Modest Improvement in Demand, Revenue Growth Return Imminent

    Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

    Rating
    Price Target
     
  • Insider-sentiment data from Vickers Stock Research reflects nice relative

    Insider-sentiment data from Vickers Stock Research reflects nice relative improvement this week, with the caveat that transaction volume is cyclically low as corporate insiders are currently broadly prohibited from trading due to earnings season. Even so, the one-week sell/buy ratios from Vickers are all in the lower (positive) zone of the neutral range after having spent the past few weeks in the middle to upper range of that same neutral zone. That has led to either slight improvement or at least a plateauing in the eight-week sell/buy readings, all of which are squarely in the middle of the neutral range. And with all the issues in play right now (the U.S. election, the Middle East, the Fed's next move, the behavior of Treasury yields, the ultimate quality of the current earnings season, etc.), neutral seems to be a reasonable posture to take at the moment. On a sector basis, insider selling outpaced buying in the Consumer Discretionary sector, with shares valued at roughly $63 million sold versus less than $5 million bought. Selling by insiders was also evident in the Financial sector, with shares valued at $42 million sold versus less than $3 million bought, as well as in the Industrial sector, with $33 million sold versus $1 million bought. This week, analysts at Vickers highlighted insider transactions of interest at PBF Energy Inc. (NYSE: PBF) and Philip Morris International Inc. (NYSE: PM).

     
  • Thermo Fisher Earnings: Modest Improvement in Demand, Revenue Growth Return Imminent

    Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

    Rating
    Price Target
     

People Also Watch